MX2020009492A - Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin. - Google Patents

Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin.

Info

Publication number
MX2020009492A
MX2020009492A MX2020009492A MX2020009492A MX2020009492A MX 2020009492 A MX2020009492 A MX 2020009492A MX 2020009492 A MX2020009492 A MX 2020009492A MX 2020009492 A MX2020009492 A MX 2020009492A MX 2020009492 A MX2020009492 A MX 2020009492A
Authority
MX
Mexico
Prior art keywords
pharmaceutical combination
ezetimibe
rosuvastatin
combination preparation
losartan
Prior art date
Application number
MX2020009492A
Other languages
Spanish (es)
Inventor
Yong Il Kim
Ho Taek Im
Hyuk Jun Cho
Jeong Hyeon Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67986281&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020009492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2020009492A publication Critical patent/MX2020009492A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)

Abstract

The present invention relates to a pharmaceutical combination preparation comprising ezetimibe and rosuvastatin. The pharmaceutical combination preparation has a water activity of 0.40 or less. The pharmaceutical combination preparation can further comprise one or more ingredients selected the group consisting of amlodipine, losartan, and combinations thereof, and the ezetimibe is present in a physically separated state from rosuvastatin, amlodipine, and losartan, respectively.
MX2020009492A 2018-03-19 2019-03-11 Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin. MX2020009492A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020180031536A KR102569271B1 (en) 2018-03-19 2018-03-19 Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin
PCT/KR2019/002769 WO2019182276A1 (en) 2018-03-19 2019-03-11 Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin

Publications (1)

Publication Number Publication Date
MX2020009492A true MX2020009492A (en) 2021-01-15

Family

ID=67986281

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009492A MX2020009492A (en) 2018-03-19 2019-03-11 Pharmaceutical combination preparation comprising ezetimibe and rosuvastatin.

Country Status (10)

Country Link
KR (1) KR102569271B1 (en)
CN (1) CN111886003A (en)
CO (1) CO2020010204A2 (en)
EA (1) EA202092189A1 (en)
MX (1) MX2020009492A (en)
PH (1) PH12020500656A1 (en)
SG (1) SG11202007869WA (en)
TW (1) TW201944992A (en)
WO (1) WO2019182276A1 (en)
ZA (1) ZA202004982B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102500643B1 (en) * 2019-04-18 2023-02-16 한미약품 주식회사 Pharmaceutical combination preparation comprising ezetimibe and losartan
WO2021226561A1 (en) * 2020-05-07 2021-11-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Covid-19 therapeutics and methods of treatment
BR112023003323A2 (en) * 2020-08-25 2023-03-21 Daewoong Pharmaceutical Co Ltd PHARMACEUTICAL COMPOSITION IN SINGLE DOSAGE FORM
GB2622822A (en) * 2022-09-28 2024-04-03 Novumgen Ltd A rapidly disintegrating tablet of rosuvastatin and its process of preparation
KR20250161310A (en) 2024-05-08 2025-11-17 한미약품 주식회사 Composite formulation having enhanced adaptability of taking medicine for oral administration comprising ezetimibe, rosuvastatin and empagliflozin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
ES2802252T3 (en) * 2012-05-01 2021-01-18 Althera Life Sciences Llc Oral tablet formulation consisting of the fixed combination of rosuvastatin and ezetimibe for the treatment of hyperlipidaemia and cardiovascular diseases
CN103585157B (en) * 2013-11-13 2016-02-03 武汉武药科技有限公司 A kind of double-layer tablet containing Ezetimibe and Rosuvastatin and preparation method thereof
KR101910901B1 (en) * 2013-11-29 2018-10-24 한미약품 주식회사 Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin
KR20150079373A (en) * 2013-12-30 2015-07-08 한미약품 주식회사 Composite formulation for oral administration comprising ezetimibe and rosuvastatin
EP3243506A1 (en) * 2016-05-09 2017-11-15 Adamed sp. z o.o. Pharmaceutical composition

Also Published As

Publication number Publication date
ZA202004982B (en) 2023-02-22
KR20190109892A (en) 2019-09-27
KR102569271B1 (en) 2023-08-23
CO2020010204A2 (en) 2020-08-31
TW201944992A (en) 2019-12-01
PH12020500656A1 (en) 2021-06-21
WO2019182276A1 (en) 2019-09-26
CN111886003A (en) 2020-11-03
EA202092189A1 (en) 2020-12-14
SG11202007869WA (en) 2020-09-29

Similar Documents

Publication Publication Date Title
PH12020500656A1 (en) Pharmaceutical combination preparation comprising ezetimide and rosuvastatin
PH12021550187A1 (en) Pyrrolopyrimidine itk inhibitors
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
PH12018502268A1 (en) Amide-substituted pyridinyltriazole derivatives and uses thereof
EP4327880A3 (en) Solid state form of ribociclib succinate
MX2020006596A (en) Hydroxyisoxazolines and derivatives thereof.
CA3010568A1 (en) Oromucosal nanofiber carriers for therapeutic treatment
WO2017121646A8 (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
HK1257296A1 (en) New compounds and their uses
MX2018015872A (en) Benzodioxane derivatives and their pharmaceutical use.
EA201891612A1 (en) DERIVATIVES 3- (CARBOXYMETHYL) -8-AMINO-2-OXO-1,3-DIAZASPIRO [4.5] DEAN
WO2017015408A8 (en) Hygiene fragrance compositions
WO2016159567A3 (en) Composition for promoting hair growth or hair restoration and for anti-inflammation
WO2018004281A3 (en) Tranexamic acid-peptide having skin whitening activity and uses thereof
WO2019103875A3 (en) Methods of using and compositions containing dulaglutide
WO2015130547A8 (en) Bis-cyclic guanidine compound compositions, methods of use and treatment thereof
EP4269549A3 (en) Skin cleansing compositions
WO2016186335A3 (en) Oral composition for cavity prevention and treatment including mulberry root extract and euonymus alatus extract as effective ingredients
WO2016019312A3 (en) Vmat inhibitory compounds
CR20230365A (en) Gitr antagonists and methods of using the same
WO2017067664A9 (en) Oxa-diazaspiro compounds having activity against pain
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof
WO2020086650A3 (en) Novel compounds
WO2016144704A3 (en) Heterocyclic autotaxin inhibitor compounds
MX2021004804A (en) Novel organoleptic compounds.